Google
Support independent publishing: buy this book on Lulu.

Monday, November 22, 2010

CANCER MAKES ITS OWN BLOOD VESSELS




Ten years ago, Mary Hendrix prevented the possible ineffectiveness of the first angiogenesis inhibitor, Avastin (bevacizumab) against melanoma cells, as these seemed to be making its own vascular bed to facilitate its nutrition. In present days, 2 studies that used samples of glioblastoma brain tumors, demonstrated the existence of blood vessels produced by cancer cells themselves, characterized by an extensive network of abnormal vessels (endothelial hyperplasia and glomeruloid structures) near the tumor with genetic markers typical of glioblastoma. Glioblastoma cells have a subpopulation of CD133+ multipotent stem cells capable of differentiation in tumor and endothelial lineages.

A first study performed in laboratory dishes, led by Viviane Tabar (Memorial Sloan-Kettering Cancer Center/NY), demonstrated the ineffectiveness of Avastin to inhibit angiogenesis induced by glioblastomas. Avastin inhibited the maturation of endothelial progenitor cells in the endothelium, but not the differentiation of CD133+ cells into endothelial progenitors. A second study led by Ruggero De Maria (Italian National Institute of Health / Rome), killed between 20-90% of glioblastoma cells after choking nutrient blood vessels of tumor cells. Today it is expected that combination therapy against tumor cells and blood vessels will remove a large number of cancers.

CANCER FABRICA SUS PROPIOS VASOS SANGUINEOS

Hace 10 años Mary Hendrix, previno la posible ineficacia del primer inhibidor de la angiogenesis : Avastin (Bevacizumab), frente a células de melanoma, ya que estas parecían estar fabricando su propio lecho vascular para facilitar su nutrición. En días actuales, 2 estudios que emplearon muestras de tumores de glioblastoma cerebral, demostraron la existencia de vasos sanguíneos fabricados por las propias células cancerosas, caracterizados por una extensa red de vasos anormales (estructuras glomeruloides e hiperplasia endotelial), cercanas al tumor con marcadores genéticos típicos de glioblastoma. Las células de glioblastoma poseen una subpoblacion de células madre CD133+ multipotente, capaz de diferenciacion en linajes tumoral y endotelial.
Un primer estudio realizado en discos de laboratorio, liderado por Viviane Tabar (Memorial Sloan-Kettering Cancer Center/NY), demostro la ineficacia del Avastin para inhibir la angiogenesis inducida por glioblastomas. El Avastin inhibio la maduracion de celulas progenitoras endoteliales en endotelio, pero no la diferenciación de las células CD133+ en progenitores endoteliales. Un segundo estudio liderado por Ruggero De Maria (Italian National Institute of Health/Rome), mato entre 20-90 % de celulas de glioblastoma, tras estrangular vasos sanguineos nutrientes de celulas tumorales. Hoy se espera que terapias combinadas contra células tumorales y vasos sanguíneos eliminen un gran numero de canceres.

Labels:

0 Comments:

Post a Comment

<< Home